title: Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy.
abstract: Background. Immunohistochemical markers were often used to classify breast cancer into subtypes. The aim of this study was to estimate death and tumor progression for patients with the major subtypes of breast cancer as classified using immunohistochemical assay and to investigate the patterns of benefit from the therapies over the past years. Methods. The study population included primary, operable 199 invasive ductal breast cancer patients, with the median age of 51.1 years old. All patients underwent local and/or systemic treatments. The clinicopathological characteristics and clinical outcomes were retrospectively reviewed. The expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki67 was analyzed by immunohistochemistry. All patients were classified into the following categories: luminal A, luminal B, HER2 overexpression, and triple-negative subtypes. Result. The median follow-up time was 33 months. Luminal A tumors had the lowest rate of tumor progression (0%, P = 0.006), while luminal B, HER2 over-expression, and triple-negative subtypes were associated with an increased risk of tumor progression (15.4, 19.2, 15.4%). Clinicopathological subtypes retained independent prognostic significance (P = 0.008). There were significant differences by Cox model analyzed in age, menopause, lymph node metastasis, and HER2 for the event of death and tumor progression (P < 0.05), and there were significant differences only in chemotherapy for the event, respectively (P < 0.05). Conclusion. Clinicopathological subtypes of breast cancer could robustly identify the risk of death and tumor progression and were significant in making therapeutic decision. HER2 was the important poor indicator. The chemotherapy intensity would be enhanced for patients with luminal B, especially for HER2 over-expression subgroup.
authors: Department of Breast Surgery, Shengjing Hospital of China Medical University, Sanhao Street No. 36, Heping District, Shenyang, Liaoning 110004, China.
authors: Jianyi
authors: J
authors: Li
authors: Shi
authors: S
authors: Jia
authors: Wenhai
authors: W
authors: Zhang
authors: Yang
authors: Y
authors: Zhang
authors: Xiang
authors: X
authors: Fei
authors: Rui
authors: R
authors: Tian
references: J Clin Oncol. 1999 May;17(5):1474-81
references: 10334533
references: Gan To Kagaku Ryoho. 2004 Feb;31(2):176-80
references: 14997747
references: Schweiz Med Wochenschr. 1977 Jul 16;107(28):1005-7
references: 897632
references: Cancer. 2007 May 1;109(9):1721-8
references: 17387718
references: BMC Res Notes. 2011 Nov 16;4:500
references: 22088140
references: Value Health. 2009 Nov-Dec;12 Suppl 3:S82-4
references: 20586989
references: CA Cancer J Clin. 2011 Nov-Dec;61(6):409-18
references: 21969133
references: World J Surg. 2011 Oct;35(10):2196-202
references: 21853356
references: Tumori. 2010 Nov-Dec;96(6):875-88
references: 21388048
references: J Natl Cancer Inst. 2009 May 20;101(10):736-50
references: 19436038
references: Ann Oncol. 2010 Jun;21(6):1323-1360
references: 19948741
references: Health Technol Assess. 2009 Jun;13 Suppl 1:7-13
references: 19567208
references: J Natl Cancer Inst. 2009 Dec 16;101(24):1730; author reply 1730-1
references: 19893007
references: Ann Oncol. 2011 Aug;22(8):1736-47
references: 21709140
references: Adv Anat Pathol. 2012 Jan;19(1):39-53
references: 22156833